Advertisement

Topics

Latest "CHMP First Biosimilar Herceptin Another Version Humira" News Stories

02:51 EST 16th December 2018 | BioPortfolio

Here are the most relevant search results for "CHMP First Biosimilar Herceptin Another Version Humira" found in our extensive news archives from over 250 global news sources.

More Information about CHMP First Biosimilar Herceptin Another Version Humira on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about CHMP First Biosimilar Herceptin Another Version Humira for you to read. Along with our medical data and news we also list CHMP First Biosimilar Herceptin Another Version Humira Clinical Trials, which are updated daily. BioPortfolio also has a large database of CHMP First Biosimilar Herceptin Another Version Humira Companies for you to search.

Showing "CHMP First Biosimilar Herceptin Another Version Humira" News Articles 1–25 of 6,700+

Saturday 15th December 2018

Week in Review: Two China Biopharmas Raise $1.4 Billion in Hong Kong IPOs

Deals and Financings  WuXi AppTec, China's largest CRO/CMO, completed its $967 million IPO in Hong Kong and finished its first trading day at the offer price; Shanghai Junshi Bioscience will raise up to $414 million in a Hong Kong IPO to support its antibody portfolio, including the first PD-1 candidate with an accepted China NDA; WuXi Biologics formed a $450 million partnership with Oxford ...


Celltrion, $TEVA; FDA Approval of HERZUMA® a Biosimilar to HERCEPTIN®, for the Treatment of HER2-Overexpressing Breast Cancer for Certain Indications https://www.businesswire.com/news/home/20181214005566/en/Celltrion-Teva-Announce-FDA-Approval-HERZUMA%C

Celltrion, $TEVA; FDA Approval of HERZUMA® a Biosimilar to HERCEPTIN®, for the Treatment of HER2-Overexpressing Breast Cancer for Certain Indications https://www.businesswire.com/news/home/20181214005566/en/Celltrion-Teva-Announce-FDA-Approval-HERZUMA%C2%AE-trastuzumab-pkrb …

Pharmaceutical Development is discussed on "Information Matrix" with Laurence Fishburne

An upcoming episode of the popular program will discuss the process of bringing pharmaceuticals to market. FORT LAUDERDALE, Fla. (PRWEB) December 15, 2018 On an upcoming episode of “Information Matrix” opened by Laurence Fishburne, the topic of discussion will be Pharmaceutical Development in the United States. The process of bringing a pharmaceutical drug to the market is a long and often ar...


Friday 14th December 2018

Innovent’s Avastin #biosimilar clears hurdle in China trials, putting company giant step closer to bringing it to market

Innovent’s Avastin #biosimilar clears hurdle in China trials, putting company giant step closer to bringing it to market

Celltrion Healthcare Co Ltd 091990 Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 23102018] Prices from USD $250

SummaryCelltrion Healthcare Co Ltd Celltrion is engaged in distributing, marketing and selling of biosimilar and biological medicines. Its products include Remsima and Truxima. Remsima is a biosimilar monoclonal antibody medication used for autoimmune diseases, including Crohn's disease CD, ulcerative colitis, rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis and plaque psoriasis. ...

. @UCSF scientists use a modified version of #CRISPR to reverse genetic forms of severe obesity in two different mouse models, without carrying out any genome editing: http://ow.ly/5mib30mZrDX 

. @UCSF scientists use a modified version of #CRISPR to reverse genetic forms of severe obesity in two different mouse models, without carrying out any genome editing: http://ow.ly/5mib30mZrDX 

Celltrion and Teva Announce FDA Approval of HERZUMA® (trastuzumab-pkrb), a Biosimilar to HERCEPTIN®, for the Treatment of HER2-Overexpressing Breast Cancer for Certain Indications

Celltrion, Inc. (KRX:068270) and Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that the U.S. Food and Drug Administration (FDA) has approved HERZUMA

Systems Oncology Announces Pipeline of Innovative Drugs Emerging from the Use of Artificial Intelligence

Dr. Spyro Mousses, CEO of Systems Oncology, LLC, announced Systems Oncology’s diversified pipeline of innovative oncology programs discovered with the help of Artificial Intelligence at the AIMed North America Conference in Dana Point, California. Systems Oncology, an AI-based biopharmaceutical company, utilizes computational tools and machine l...

Biosimilar Approved By FDA For Treating HER2-overexpressing Breast Cancer

The FDA has approved trastuzumab-pkrb (Herzuma, Celltrion) as a biosimilar to trastuzumab (Herceptin, Genentech) for the treatment of HER2-overexpressing breast cancer. 

Providence Hospital Emergency Department Remains Open and Fully Staffed, 24/7

This is to clarify a previous communication regarding Providence Hospital operations. Providence’s Emergency Care Center remains open, fully staffed, and available to serve the District of Columbia community, with the same range of services that we have always provided to support our emergency care patients, including an inpatient unit, lab, diagnostic i...

Roche-Medikament Herceptin erhält in den USA Konkurrenz

Zürich (awp) - In den USA erhält das Roche-Krebsmedikament Herceptin in der Behandlung von HER2-positivem Brustkrebs Konkurrenz. Die US-Gesundheitsbehörde hat Herzuma der Pharmafirma Celltrion als ...

PDA Announces Diverse 2019 Board of Directors

PDA's 2019 Board of Directors is one of them of the most diverse boards in the pharmaceutical industry. BETHESDA, Md. (PRWEB) December 14, 2018 The Parenteral Drug Association (PDA) today announced the results of its Board of Directors Election for the term beginning January 1, 2019. In the fall of 2018, PDA’s 10,500 members had an opportunity to participate in the election of new directors...

Validation of the short version of the Van Lieshout Test in an Italian population with cervical spinal cord injuries: a cross-sectional study

BIO Statement on Hatch-Waxman Integrity Act of 2018

Biotechnology Innovation Organization (BIO) President & CEO James C. Greenwood today issued the following statement on the Hatch-Waxman Integrity Act of 2018: “For almost 40 years, the groundbreaking law known as the Hatch-Waxman Act (HWA) has been highly successful in spurring the development of life-saving new treatments while at the same ...

Edmonton to Host Clinical Trial for Nova Oculus Medical Device that Could Help Improve Vision for AMD Sufferers

Health Canada approves study for pioneering treatment EDMONTON, Alberta (PRWEB) December 14, 2018 NOVA OCULUS PARTNERS, LLC, and its Canadian partner, the Eye Machine Canada Inc., have been given the green light to immediately begin a clinical patient trial in Edmonton using their pioneering technology for treating Age-Related Macular Degeneration (AMD). The medical devices bureau of Health Canad...

Prestige BioPharma Partners with Cipla to Market Key Cancer Biosimilar

NewsThe licensing agreement for the HD20 trastuzumab biosimilar gives Cipla Ltd. exclusive rights to distribute and market the drug in selected emerging markets.

Pfizer's cut-price version of Avastin wins EU panel greenlight

A panel of European Medicines Agency (EMA) on Friday recommended approval for Pfizer Inc's Zirabev, a cheaper version to Roche Holding AG's leading cancer drug Avastin.

2018 TripleTree iAwards – Finalists Announced

TripleTree, LLC, a strategic advisor and merchant bank serving innovative and market-leading healthcare technology and services companies, is pleased to announce the five finalists for the 2018 TripleTree iAwards. Finalists were evaluated and selected based on the impact of their transformative capabilities and their potential to address some of the most p...

Trastuzumab Biosimilar CT-P6 Shows Comparable Efficacy at 2-Year Follow-up

CT-P6, a proposed biosimilar to trastuzumab, exhibited long-term disease-free survival and overall survival similar to the reference product in the treatment of patients with HER2-positive early breast cancer.

Takeda Receives Positive CHMP Opinion for ADCETRIS® (brentuximab vedotin) for the Treatment of Adult Patients with Previously Untreated CD30+ Stage IV Hodgkin Lymphoma in Combination with AVD

– If Authorized in Europe, ADCETRIS in Combination with AVD (Adriamycin, Vinblastine and Dacarbazine) Will Be the First New Treatment Regimen Available for Adult Patients with Previously Untreated CD30+ Stage IV Hodgkin Lymphoma in Decades – – Opinion Based on Positive Phase 3 ECHELON-1 Study Results, Which Demonstrated ADCETRIS Combination ...

Advaxis Stumbles Further As Amgen Exits Early-Stage Cancer Immunotherapy Pact

Troubled by a clinical hold for another program, Advaxis now regains all rights to ADXS-NEO, a personalized immunotherapy in Phase...   

Warnings Up As US FDA Trims List Of Uninspected OTC Drug Manufacturers

Hundreds of foreign firms making OTC drugs marketed in US had not been inspected for GMPs compliance before FDA Safety...   

CHMP Recommends Approval of Opioid-Induced Constipation Drug

The European Medicines Agency's committee recommended approval of the mu-opioid receptor antagonist for treatment of opioid-induced constipation in adults previously been treated with a laxative. News Alerts

FDA approves Celltrion's Herceptin biosimilar

Pfizer Receives Positive CHMP Opinion for Oncology Biosimilar, ZIRABEV™ (bevacizumab)

ZIRABEV™ (bevacizumab), a potential biosimilar to Avastin®* (bevacizumab), is Pfizer’s second therapeutic oncology biosimilar to receive a positive CHMP opinion in Europe in 2018 Pfizer Inc. (NYSE:PFE) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive...


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks